Medtronic said on 16 November 2026 it would acquire Contego Medical, a privately held developer of carotid and peripheral vascular devices, in a deal valued at US$380m with potential payments after closing.
Why Medtronic plc is buying Contego Medical, Inc.
The deal adds the Neuroguard IEP Direct System, a transcarotid revascularisation system with integrated embolic protection and flow reversal, and Excipio thrombectomy devices that complement Medtronic's Liberant system. David Moeller, president of Medtronic Peripheral Vascular Health, said Medtronic intends to become an undisputed leader in carotid revascularisation.
Deal terms and financing
Medtronic expects the deal to be minimally dilutive to adjusted EPS in fiscal 2027 and 2028 and neutral to accretive thereafter.
Regulatory approvals and timing
Completion is expected in Medtronic's fiscal third quarter, subject to customary closing conditions.
Market context
Medtronic has been a minority investor in Contego since 2020 and became its exclusive US distributor in January 2025 under an agreement that included an option to acquire the company. Contego's investors include Hatteras Venture Partners, U.S. Venture Partners, Lightstone Ventures and Amzak Health.






